Analysts Are Bullish on These Healthcare Stocks: AEON Biopharma (AEON), Palatin Technologies (PTN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AEON Biopharma (AEON – Research Report), Palatin Technologies (PTN – Research Report) and IN8bio (INAB – Research Report) with bullish sentiments.

AEON Biopharma (AEON)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on AEON Biopharma today and set a price target of $6.00. The company’s shares closed last Wednesday at $1.51, close to its 52-week low of $1.38.

According to TipRanks.com, Tsao is a 4-star analyst with an average return of 3.9% and a 37.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Crinetics Pharmaceuticals, and Protagonist Therapeutics.

Currently, the analyst consensus on AEON Biopharma is a Moderate Buy with an average price target of $6.00.

See the top stocks recommended by analysts >>

Palatin Technologies (PTN)

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Palatin Technologies today and set a price target of $17.00. The company’s shares closed last Wednesday at $2.04, close to its 52-week low of $1.43.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 13.0% and a 42.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Cadrenal Therapeutics, Inc.

Currently, the analyst consensus on Palatin Technologies is a Strong Buy with an average price target of $9.33.

IN8bio (INAB)

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on IN8bio, with a price target of $5.00. The company’s shares closed last Wednesday at $1.03, close to its 52-week low of $0.65.

According to TipRanks.com, Roy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.8% and a 28.8% success rate. Roy covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Acrivon Therapeutics, Inc., and Deciphera Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IN8bio with a $8.25 average price target, a 693.3% upside from current levels. In a report issued on May 9, Mizuho Securities also maintained a Buy rating on the stock with a $8.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AEON:

• Aeon Biopharma provides update on development pipeline
• Aeon’s results from Phase 2 trial of ABP-450 didn’t meet primary endpoint
• AEON Biopharma Phase 2 Migraine Treatment Trial Results
• AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
• AEON Biopharma Bolsters Finance and Board with Daewoong Deal